Projecting benefits and harms of novel cancer screening biomarkers: A study of PCA3 and prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 4, 2015, Pages 677-682

  Birnbaum, Jeanette K ^a   Feng, Ziding ^a,b,c   Gulati, Roman ^c   Fan, Jing ^a   Lotan, Yair ^d   Wei, John T ^e   Etzioni, Ruth ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; EARLY DIAGNOSIS; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; UNITED STATES; VALIDATION STUDY; BLOOD; COMPUTER SIMULATION; EARLY CANCER DIAGNOSIS; FALSE POSITIVE RESULT; HEALTH SERVICE; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROCEDURES; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY;

AGED; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; COMPUTER SIMULATION; EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; HUMANS; MALE; MEDICAL OVERUSE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84927916888     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-1224     Document Type: Article

References (32)

1. Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Future Oncol Lond Engl 2005;1:37-50.
2. Srinivas PR, Kramer BS, Srivastava S. Trends in biomarker research for cancer detection. Lancet Oncol 2001;2:698-704.
3. Manne U, Srivastava R-G, Srivastava S. Recent advances in biomarkers for cancer diagnosis and treatment. Drug Discov Today 2005;10: 965-76.
4. Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards amore accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007;6:308-12.
5. Srivastava S, Kramer BS. Early detection cancer research network. Lab Investig J Tech Methods Pathol 2000;80:1147-8.
6. National Cancer Institute. Objectives-EDRN Public Portal [Internet]. [cited 2011 Aug 26]. Available from: http://edrn.nci.nih.gov/about-edrn/objectives/
7. Auprich M, Bjartell A, Chun FK-H, de la Taille A, Freedland SJ, Haese A, et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol 2011;60:1045-54.
8. Tombal B, Ameye F, de la Taille A, de Reijke T, Gontero P, Haese A, et al. Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion. World J Urol 2012;30:251-6
9. De la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 2011;185:2119-25.
10. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SMJ, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69:532-5.
11. Deras IL, Aubin SMJ, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587-92.
12. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009;6:255-61.
13. Rigau M, Ortega I, Mir MC, Ballesteros C, Garcia M, Llauradó M, et al. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer. The Prostate 2011;71:1736-45.
14. Durand X,Moutereau S, Xylinas E, de la Taille A. ProgensaTM PCA3 test for prostate cancer. Expert Rev Mol Diagn 2011;11:137-44.
15. Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol 2014;32:4066-72.
16. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
17. Roobol MJ. Contemporary role of prostate cancer gene 3 in the management of prostate cancer. Curr Opin Urol 2011;21:225-9.
18. Gulati R, Inoue L, Katcher J, Hazelton W, Etzioni R. Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics 2010;11:707-19.
19. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
20. Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 2005; 174:877-81.
21. Roobol MJ, Schröder FH, van Leenders GLJH, Hessels D, van den Bergh RCN, Wolters T, et al. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥100). Eur Urol 2010;58:893-9.
22. Shappell SB, Fulmer J, Arguello D, Wright BS, Oppenheimer JR, Putzi MJ. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology 2009;73:363-8.
23. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008;179:1804-9; discussion 1809-10.
24. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364:1708-17.
25. Wever EM, Draisma G, Heijnsdijk EAM, de Koning HJ. How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening. Med Decis Mak Int J Soc Med Decis Mak 2011;31:550-8.
26. Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366:981-90.
27. Van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, de Reijke T, et al. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int 2012;109:360-6.
28. Haese A, de la Taille A, van Poppel H,MarbergerM, Stenzl A, Mulders PFA, et al. Clinical utility of the PCA3 urine assay in Europeanmen scheduled for repeat biopsy. Eur Urol 2008;54:1081-8.
29. Gulati R,Wever EM,Tsodikov A, PensonDF, Inoue LYT, Katcher J, et al.What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev 2011;20:740-50.
30. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for Prostate Cancer: a review of the evidence for theU.S. Preventive Services Task Force. Ann Intern Med 2011;155:762-71.
31. Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol 2008;180:1303-8; discussion 1308.
32. Aubin SMJ, Reid J, SarnoMJ, Blase A, Aussie J, Rittenhouse H, et al. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial. Urology 2011;78:380-5.